Physician profile
Whitney E Molis
NPI 1396724878
$3,590.74
in general payments reported to CMS, 2019-2025
18 companies · $809 in 2025
The $809 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $207 · 2021: $379 · 2022: $602 · 2023: $492 · 2024: $597 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.74 |
| Education | $230.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,710.98 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $836.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $332.01 | 2019-2025 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $287.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.86 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $57.25 | 2025 | |
| Amgen INC. | $48.56 | 2022-2025 | |
| Jubilant Hollisterstier LLC | $39.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.46 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $32.63 | 2025 | Neffy |
| Kaleo, INC. | $31.90 | 2019-2023 | Auvi-Q |
| Galderma Laboratories, L.P. | $28.64 | 2025 | Nemluvio |
| Biocryst US Sales Co., LLC | $17.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.33 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.22 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.60 | 2022 | |
| Optinose US, INC. | $13.64 | 2019 | |
| Alk-Abello, INC | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Molis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.